Literature DB >> 9930676

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.

N Dimasi1, A Pasquo, F Martin, S Di Marco, C Steinkühler, R Cortese, M Sollazzo.   

Abstract

The polyprotein encoded by hepatitis C virus (HCV) genomic RNA is processed into functional polypeptides by both host- and virus-encoded proteases. The HCV-encoded NS3 protease and its cofactor peptide NS4A form a non-covalent complex, which participates in processing the viral polyprotein. This proteolytic activity is believed to be essential for virus proliferation and thus the NS3 protease is a prime target for developing anti-HCV pharmacological agents. Recent X-ray crystallography structural studies have revealed the nature of this non-covalent complex between NS3 protease and the 'active' central segment of NS4A, providing the opportunity to design a single-chain polypeptide. To this end, the DNA sequence encoding for the NS4A peptide (residues 21-34) was genetically fused via a short linker, capable of making a beta-turn, to the N-terminus of the NS3 protease domain. This engineered single-chain NS3-protease (scNS3) is fully active with kinetic parameters virtually identical with those of the NS3/ NS4A non-covalent complex. Moreover, the scNS3 protease can be displayed on filamentous phage and affinity selected using an immobilized specific inhibitor. The scNS3 expressed as a soluble protein and in a phage-display format facilitates enzyme engineering for further structural studies and in vitro selection of potential drug-resistant mutants. These are important steps towards developing effective anti-protease compounds.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930676     DOI: 10.1093/protein/11.12.1257

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  8 in total

1.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Conformational changes in redox pairs of protein structures.

Authors:  Samuel W Fan; Richard A George; Naomi L Haworth; Lina L Feng; Jason Y Liu; Merridee A Wouters
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

3.  High affinity peptide inhibitors of the hepatitis C virus NS3-4A protease refractory to common resistant mutants.

Authors:  Jonas Kügler; Stefan Schmelz; Juliane Gentzsch; Sibylle Haid; Erik Pollmann; Joop van den Heuvel; Raimo Franke; Thomas Pietschmann; Dirk W Heinz; John Collins
Journal:  J Biol Chem       Date:  2012-09-10       Impact factor: 5.157

4.  Autocatalytic cleavage within classical swine fever virus NS3 leads to a functional separation of protease and helicase.

Authors:  Benjamin Lamp; Christiane Riedel; Eveline Wentz; Maria-Alejandra Tortorici; Till Rümenapf
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

5.  Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells.

Authors:  Rosario Sabariegos; Fernando Picazo; Beatriz Domingo; Sandra Franco; Miguel-Angel Martinez; Juan Llopis
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

6.  Differential requirements of NS4A for internal NS3 cleavage and polyprotein processing of hepatitis C virus.

Authors:  Yi-Hen Kou; Ming-Fu Chang; Yi-Ming Wang; Tzu-Min Hung; Shin C Chang
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

7.  Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.

Authors:  Miguel Angel Martinez; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.

Authors:  Assaf Shapira; Meital Gal-Tanamy; Limor Nahary; Dana Litvak-Greenfeld; Romy Zemel; Ran Tur-Kaspa; Itai Benhar
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.